OX2 Therapeutics Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $649K
Latest Deal Amount
  • Investors
  • 1

OX2 Therapeutics General Information

Description

Operator of a healthcare therapeutics company intended to treat primary brain tumors. The company's novel CD200 Checkpoint peptide inhibitor activates the immune system through a CD200 activation receptor, enabling healthcare institutes to apply receptor antibodies that permit the immune system army to pass through blood vessel walls and kill cancer activities.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 1621 East Hennepin Avenue
  • Suite 290
  • Minneapolis, MN 55414
  • United States
+1 (612) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OX2 Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 21-Sep-2020 $649K 00.000 Completed Generating Revenue
2. Early Stage VC (Series A) 18-May-2017 000 000 000 Completed Generating Revenue
1. Grant $2M Completed Startup
To view OX2 Therapeutics’s complete valuation and funding history, request access »

OX2 Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view OX2 Therapeutics’s complete cap table history, request access »

OX2 Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Michael Olin Ph.D Co-Founder, Chief Scientific Officer & Board Member
Christopher Moertel MD Co-Founder & Chief Medical Officer
Sumant Dhawan Vice President of Operations, Co-Founder & Board Member
Jeff Liter President, Interim Chief Financial Officer & Interim Chief Executive Officer
To view OX2 Therapeutics’s complete executive team members history, request access »

OX2 Therapeutics Board Members (6)

Name Representing Role Since
Andrea Hunt Self Board Member 000 0000
Ben Oehler OX2 Therapeutics Board Member 000 0000
Michael Olin Ph.D OX2 Therapeutics Co-Founder, Chief Scientific Officer & Board Member 000 0000
Rob Parish Self Board Member 000 0000
Sumant Dhawan OX2 Therapeutics Vice President of Operations, Co-Founder & Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

OX2 Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OX2 Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Minnesota State University, Mankato Foundation University 000 0000 000000 0
To view OX2 Therapeutics’s complete investors history, request access »